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Genome-wide association studies have already yielded 
great results. The success of this method in several 
common diseases leaves little doubt that it will aid in 
deciphering the genetic bases of the most common and 
devastating neurodegenerative disorders.
Introduction
In the past two decades, spectacular progress has been 
made in the identification of mutations underlying 
Mendelian (monogenic) neurodegenerative diseases. 
Unbiased, genome-wide linkage analysis and positional 
cloning in large pedigrees have been keys to success. 
In some instances, the identification of genes causing 
rare Mendelian forms provided important insights for 
understanding the pathogenesis of a disease in general. 
However, monogenic models appear inadequate to 
explain most cases of common neurodegenerative disorders, 
such as Alzheimer’s diseases (AD), Parkinson’s disease (PD), 
or amyotrophic lateral sclerosis (ALS). A more plausible 
hypothesis is that such “complex” diseases are determined 
by several genetic factors (each contributing a part of the 
total genetic risk), as well as by nongenetic factors and 
their interplay. The number of genetic factors involved and 
their individual effect size (the genetic architecture), as well 
as their interaction, are likely to be specific not only for a 
certain disease but also for a certain population. In this 
context, another leading hypothesis is that the susceptibility 
to common diseases is determined by gene variants that are 
also common in the population. 
Linkage analysis approaches are of limited validity for the 
dissection of complex diseases. A more promising approach 
is to directly compare large series of cases and unrelated 
controls using genetic markers (case-control study) [1,2]. 
If a certain genetic variant (allele A) is significantly more 
frequent (or more rare) among cases than among controls, 
the A variant (or another variant located nearby on the 
chromosome), said to be “in linkage disequilibrium” with A 
might be a risk (or a protective) factor for the disease. In the 
past, this approach has been extensively applied to candidate 
genes, but only rarely have the results been replicated.
Genome-wide Association Studies 
Some fundamental scientific and technological devel-
opments of the past few years now allow the extension 
of the allelic association design at the level of the 
whole genome (genome-wide association [GWA]) [1,2]. 
The study design remains simple: compare the cases 
and controls for a very high number of DNA variants 
(in this case single nucleotide polymorphisms [SNPs]), 
aiming at best possible coverage of the genome. In the 
ideal situation, all the several million known SNPs would 
be interrogated. Although this is still unfeasible, recent 
progress allows some good compromises.
First, the completion of the Human Genome Project 
led to the identification and annotation of the required 
large number of SNP variants. Second, the International 
Hap Map project has provided information about the 
relatedness between each SNP and the surrounding vari-
ants so that one might focus on fewer SNPs, which are 
enough to capture most of the common variability in each 
of the discrete segments composing our genome (linkage 
disequilibrium blocks). These “intelligent” SNPs are also 
called “haplotype-tagging.” The rarer SNPs (minor allele 
frequency < 1%–5%) are not relevant under the hypoth-
esis of “common variants explaining common diseases” 
and can be ignored for the purposes of this approach, 
at least in a first phase. 
Third, development in high-throughput genotyping 
platforms allows us to test the required number of SNPs 
in large numbers of cases and controls at affordable costs. 
The technology of DNA arrays currently allows hundred 
of thousands SNPs to be interrogated in a single experi-
ment, with arrays for 1 million SNPs expected soon. Some 
arrays focus on SNPs located within genes (gene-centric) 
and some focus on SNPs coding for protein variants. 
In this way, one might concentrate on variants with a high 
likelihood of biologic effects. Other arrays capitalize on 
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haplotype-tagging SNPs, whereas others interrogate ran-
domly spaced SNPs in the genome. An array of 500,000 
SNPs might yield an average inter-marker distance of 
5 kb, allowing the large “noncoding genome” to also be 
systematically investigated. 
Most GWA studies will require thousands of cases 
and controls; therefore, the collaborative efforts of mul-
tiple research centers are crucial to success. GWA studies 
also require relevant data storage and computational 
power, and a growing list of dedicated statistical tools 
is being developed. The enormous number of tests per-
formed raises unprecedented statistical challenges for the 
biologist. The threshold required to declare significant 
association at genome-wide level depends on the num-
ber of SNPs being tested, but it easily reaches orders of 
P = 10-7 or 10-8. There is debate on the best statistical treat-
ment for GWA data, and the Bonferroni correction might 
be too stringent. Others prefer permutation or Bayesian 
statistics. In any case, due to a high chance of false-posi-
tive findings, it is of crucial importance that results are 
confirmed in independent, large replication studies [1,2]. 
Will the GWA study approach be successful to dissect 
complex diseases? The results of pioneer studies generate 
optimism. In different complex diseases, including bipo-
lar disorder, type 1 and type 2 diabetes, coronary artery 
disease, rheumatoid arthritis, Crohn’s disease, breast can-
cer, and others, large-scale GWA studies have reported 
the successful confirmation of many previously known 
disease-risk genes and the identification (including repli-
cation) of several novel ones [3–6].
However, easy generalizations might be dangerous. 
In each case, the success of the GWA approach will 
depend on the genetic architecture of the disease under 
study (which is largely unknown), and particularly how 
many genes are involved, how large the effect-size is of 
each gene, and how homogeneous is the disease etiology 
in the target population. The easiest scenario will be 
that of diseases with a small number of genes involved, 
each of moderate to large effect size (odds ratio > 2) 
and distributed homogeneously in the patients from the 
population. However, other diseases could be determined 
by many more genes, some of which may have very small 
effects, and the etiologic structure might be heteroge-
neous within the population. In the last scenario, even a 
very large GWA study might be underpowered. It is also 
important to remember that current array technology 
for the GWA study approach is largely based on frequent 
SNPs, according to the “common disease – common 
variants” hypothesis. However, if many rare risk alleles 
are involved (frequency of < 5% in the population), these 
will likely remain undetected. Lastly, it is unlikely that 
a SNP yielding an association signal is the biologically 
relevant variant; more likely, it indicates another variant 
located closely within the linkage disequilibrium block. 
The real size effects (odd ratios) might therefore be 
diluted when looking at the initial SNPs signals. In other 
words, the power of the study also depends on how effi-
ciently a certain “detecting” SNP tags the biologically 
relevant variant.
GWA Studies for Neurodegenerative Diseases
Within this framework, the first GWA studies in common 
neurodegenerative diseases have been recently completed. 
Two studies examining PD [7,8] and one examining ALS [9] 
each involved less than 300 case-control pairs from the North 
American population and tested up to 400,000 SNPs. None 
of these studies identified association at the level required for 
genome-wide significance after Bonferroni correction. The 
SNPs giving the strongest association signals did not overlap 
in the two PD studies [7,8], and the most strongly associated 
SNPs identified in the first PD study [7] were not replicated 
in independent case-control samples [10,11]. It is important 
to consider that these GWA studies were underpowered to 
detect common variants of small effect sizes (odds ratios of 
< 1.5). However, one could be tempted to conclude that there 
is not a single common gene for PD or ALS with a moderate 
to large effect size. However, caution is warranted because in 
these studies [7–9] the genomic coverage cannot be considered 
complete even for common variants, the etiologic heterogene-
ity in the studied population was likely high, and rare variants 
would have remained undetected.
The great potential and also the limitations of current 
GWA studies are well illustrated by the first reported study 
of this kind in AD [12]. Five-hundred thousand SNPs 
were tested on 664 pathologically verified AD cases and 
422 controls collected at multiple centers, mostly in 
the United States. The apolipoprotein E (ApoE) locus 
emerged with spectacular statistical significance (uncor-
rected P value = 1.06 x 10-39, Bonferroni corrected P value 
for 500,000 tests = 5.30 x 10-34). The GWA approach is 
therefore able to detect genetic determinants of complex, 
late-onset neurodegenerative disease, if these determinants 
exist, and if enough SNPs are studied in large, well-char-
acterized samples. No other genome-wide significant 
signals (stronger that 10-8) were detected, but this, once 
again, is not definitive evidence for the absence of other 
genes for AD. Remarkably, the ApoE locus was detected 
by a single SNP located 14 kb away from the ApoE 
biologically relevant variants. Thus, ApoE would also 
have been missed if that single SNP was not included 
in the array. This tells us that even 500,000 SNP arrays 
might not be enough for adequate genome coverage, espe-
cially in general (outbred) populations. Other genes for 
AD might exist, perhaps even of the same size effect of 
ApoE or greater. 
In an extension of the same GWA study [13], the 
subset of cases and controls carrying the ApoE-F4 risk 
allele was mined for additional genetic determinants. 
Consistent, genome-wide evidence for association was 
found at several SNPs, nominating the GRB-associated 
binding protein 2 (GAB2) gene as a novel risk gene for 
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late-onset AD, in combination with the ApoE-F4 allele. 
Functional evidence supports a role for the Gab2 protein 
in a pathway that controls the phosphorylation of the 
protein tau, a well-known player in AD pathogenesis [13]. 
The association of the GAB2 variants with ApoE-F4–pos-
itive AD needs further confirmation, but a novel chapter 
in the genetics of AD might have been opened, also yield-
ing novel therapeutic targets.
Conclusions
We are only at the beginning of the GWA era, and this 
approach is already yielding results. Of note, more and 
more GWA teams are making raw genotype data publicly 
available to the research community for further mining 
and meta-analysis. It is likely that many more GWA stud-
ies will be performed in the near future in large samples 
from well-characterized populations. The success obtained 
in several common diseases leaves little doubt that GWA 
studies will also contribute significantly in deciphering 
the genetic bases of the most common and devastating 
neurodegenerative disorders.
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